Biomaterials Comprising Implantable and Dermal Drug Delivery Targeting Brain in Management of Alzheimer’s Disease: A Review

Alzheimer’s disease (AD) is regarded as the most common neurological condition in terms of cognition. The disease progresses gradually, begin with a slight memory loss and maybe lead to the lack of communication as well as environmental awareness. Like the majority of neurological conditions, Alzheimer’s disease has no proven effective drug and treatment of reversal. Moreover, this disorder requires a long-term treatment and a progressive supply of the induced drug. The review investigated the use of biomaterial in the fabrication of implantable and dermal drug delivery targeting the brain in the management of AD. An ideal drug-delivering system for the management of AD requires a transitional approach using advanced technology. The ability of implantable drug delivery systems to release drugs continuously and effectively over an extended period of time, and in the needed dosage, is a topic of extensive research. Several types of implantable drug delivery systems including the usage of nanotechnologies have been widely implicated in the treatment of neurological aliments. Recently, patient-centric approach-based fabrication of three-dimensional printed implants and microneedle have been investigated that demonstrated enhancement in permeability with prolonged release of medication. The current review offers a thorough grasp of the implantable drug delivery systems especially implant film and microneedle, their fabrication strategies, and their mechanisms, with a focus in the management of AD. AD is a neurodegenerative condition that affects memory, reasoning, and the capacity to carry out everyday duties. Modern therapeutic interventions have the potential to improve life expectancy but fall short of complete curing AD. Polymeric biomaterials fabricated implants and dermal microneedles that were applied directly overhead bought revolution in delivering drug and management of AD.